MPV and APV Diagnostic Reagents for Respiratory Virus Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and treatment methods for respiratory diseases in mammals, particularly humans, face challenges due to the genetic similarity between mammalian metapneumoviruses (MPV) and avian pneumoviruses (APV), making it difficult to develop specific reagents for MPV infections, and there is a need for effective diagnostic and therapeutic tools for MPV and APV infections in both mammals and birds.
Innovation Solution
The development of MPV-specific and APV-specific reagents, including nucleic acid and protein-based diagnostics, and the use of cross-reactive reagents derived from APV or MPV for diagnostic and therapeutic purposes, along with the generation of chimeric virus constructs for vaccine development, to address the genetic similarity and improve diagnostic and treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If specific reagents are developed for MPV diagnosis, then diagnostic precision is improved, but the genetic similarity to APV makes reagent development difficult
Solution Approach 1:
The patent segments the diagnostic approach by developing separate specific reagents for MPV and APV despite their genetic similarity. This involves identifying and targeting unique genomic regions or antigenic epitopes that distinguish MPV from APV, allowing for precise differentiation through segmented diagnostic strategies rather than a single universal reagent
Solution Approach 2:
The patent uses cross-reactive reagents as intermediaries that can detect both MPV and APV. These reagents are designed to recognize conserved regions shared between the two viruses, serving as a mediator that enables initial detection and screening, which can then be followed by more specific confirmation tests to distinguish between the two pathogens
2Adaptability or versatility
If cross-reactive reagents are used for both MPV and APV, then versatility is improved, but diagnostic precision may be reduced
Solution Approach 1:
The patent implements a dynamic diagnostic algorithm that adapts the interpretation of reagent results based on the testing context. When cross-reactive reagents are used, the system dynamically adjusts the threshold for positive identification and incorporates sequential testing logic, where initial cross-reactive screening is followed by confirmatory tests that resolve ambiguities and maintain diagnostic precision despite reagent versatility
Solution Approach 2:
The patent employs a multi-stage diagnostic approach where cross-reactive reagents perform partial detection functions initially, followed by additional specific reagents that complete the diagnostic process. This excessive action of using multiple reagent types ensures that even if cross-reactive reagents alone cannot provide definitive identification, the combination of reagents achieves both versatility and precision through cumulative detection
3Productivity
If combination vaccines are developed for MPV and APV, then productivity is improved, but vaccine development complexity increases
Solution Approach 1:
The patent merges MPV and APV antigens into combination vaccine constructs that can elicit protective immunity against both viruses simultaneously. This involves co-expressing viral proteins or presenting antigenic epitopes from both pathogens in a single vaccine platform, reducing the need for separate vaccination campaigns and improving overall productivity in preventing respiratory tract illnesses
Solution Approach 2:
The patent creates composite vaccine constructs that integrate components from both MPV and APV into a unified immunogenic formulation. These composite vaccines may use viral vectors or antigen presentation systems that incorporate genetic material or protein structures from both viruses, forming a composite immunological stimulus that triggers broad protective responses while managing the complexity through standardized vaccine platform technologies
Data Source
AI summary
The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single stranded RNA virus (MPV) within the subfamily Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus and components thereof.